Lancet:对乙酰氨基酚治疗腰痛无明显效果

2014-07-25 佚名 丁香园

据近期1项大规模随机试验结果表明,与安慰剂相比,对乙酰氨基酚在缓解腰痛急性发作和改善疼痛水平、功能、睡眠及生活质量上并无明显优势。对乙酰氨基酚作为治疗腰痛的首选镇痛药已经众人皆知,但该项试验对此提出了质疑。文章发表在2014年7月24日The Lancet杂志上。 腰痛已经是世界范围内致残的重要原因。大多数临床指南普遍建议对乙酰氨基酚为治疗急性腰痛的首选镇痛药,然而并没有相关的基础研究证

据近期1项大规模随机试验结果表明,与安慰剂相比,对乙酰氨基酚在缓解腰痛急性发作和改善疼痛水平、功能、睡眠及生活质量上并无明显优势。对乙酰氨基酚作为治疗腰痛的首选镇痛药已经众人皆知,但该项试验对此提出了质疑。文章发表在2014年7月24日The Lancet杂志上。

腰痛已经是世界范围内致残的重要原因。大多数临床指南普遍建议对乙酰氨基酚为治疗急性腰痛的首选镇痛药,然而并没有相关的基础研究证实对乙酰氨基酚治疗腰痛有效。

对乙酰氨基酚治疗腰痛研究小组(PACE)随机从悉尼235家初级护理中心纳入1652例腰痛患者。平均年龄45岁,随机把相同数量的患者分为常规剂量组(连续定期服用4周对乙酰氨基酚,每日3次,相当于每日3990 mg)、按需服用组(按患者需求服用,最大每日剂量不超过4000 mg)和对照组(服用安慰剂)。服药结束后,三组均接受持续3个月的随访。

试验结果显示三组在恢复时间上无明显差别,中位恢复时间分别为17天(常规剂量组),17天(按需服用组)和16天(对照组)。在缓解短期疼痛、伤残、功能、睡眠及生活质量水平上,对乙酰氨基酚的效果也不明显。而且,各组发生副作用的人数基本相等。

“像对乙酰氨基酚这样的一般镇痛药,在治疗急性腰痛患者中不应该扮演如此重要的角色。”文章第一作者,来自澳大利亚悉尼大学乔治全球健康研究院Christopher Williams博士说道,“研究结果提示,虽然对乙酰氨基酚能有效缓解其他类型疼痛,但我们应该重新评估对乙酰氨基酚作为腰痛治疗一线药物的观点,这直接关系到患者后续治疗的计划。

Williams博士还补充道:“鉴于本次试验周期较短,我们非常想知道,究竟是心理安慰还是药理作用在治疗腰痛急性发作上更为有效。”

来自荷兰鹿特丹Erasmus大学医学中心Bart Koes和Wendy Enthoven教授评论认为,“Williams博士和他的团队能够质疑我们长久以来约定俗成的观点,这是非常值得鼓励的事情。尽管本次高质量试验研究结论非常明确,但指南的修改不能基于这一次试验,而还需要更多的试验结果辅佐。此外,今后的研究可致力于其他一般的镇痛药是否会给腰痛患者带来额外的心理安慰作用。”

原始出处:

Christopher M Williams, Christopher G Maher, Jane Latimer, Andrew J McLachlan, Mark J Hancock, Richard O Day, Chung-Wei Christine Lin.Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial.The Lancet, Early Online Publication, 24 July 2014.doi:10.1016/S0140-6736(14)60805-9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1827851, encodeId=21b2182e8512c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 09 17:41:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952042, encodeId=8502195204270, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Fri Dec 12 14:41:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321767, encodeId=80881321e678d, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 27 06:41:00 CST 2014, time=2014-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10626, encodeId=2ff5106265d, content=这种研究也能发柳叶刀,真不可思议呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=123.150.123.159, createdTime=Fri Jul 25 20:42:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
    2015-07-09 howi
  2. [GetPortalCommentsPageByObjectIdResponse(id=1827851, encodeId=21b2182e8512c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 09 17:41:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952042, encodeId=8502195204270, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Fri Dec 12 14:41:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321767, encodeId=80881321e678d, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 27 06:41:00 CST 2014, time=2014-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10626, encodeId=2ff5106265d, content=这种研究也能发柳叶刀,真不可思议呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=123.150.123.159, createdTime=Fri Jul 25 20:42:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1827851, encodeId=21b2182e8512c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 09 17:41:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952042, encodeId=8502195204270, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Fri Dec 12 14:41:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321767, encodeId=80881321e678d, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 27 06:41:00 CST 2014, time=2014-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10626, encodeId=2ff5106265d, content=这种研究也能发柳叶刀,真不可思议呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=123.150.123.159, createdTime=Fri Jul 25 20:42:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1827851, encodeId=21b2182e8512c, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Thu Jul 09 17:41:00 CST 2015, time=2015-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952042, encodeId=8502195204270, content=<a href='/topic/show?id=3dbb2346632' target=_blank style='color:#2F92EE;'>#乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23466, encryptionId=3dbb2346632, topicName=乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac1c235, createdName=tonychen21, createdTime=Fri Dec 12 14:41:00 CST 2014, time=2014-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321767, encodeId=80881321e678d, content=<a href='/topic/show?id=818246618a4' target=_blank style='color:#2F92EE;'>#对乙酰氨基酚#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=46618, encryptionId=818246618a4, topicName=对乙酰氨基酚)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afdf491, createdName=lilili1104, createdTime=Sun Jul 27 06:41:00 CST 2014, time=2014-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=10626, encodeId=2ff5106265d, content=这种研究也能发柳叶刀,真不可思议呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=123.150.123.159, createdTime=Fri Jul 25 20:42:00 CST 2014, time=2014-07-25, status=1, ipAttribution=)]
    2014-07-25 123.150.123.159

    这种研究也能发柳叶刀,真不可思议呀

    0